An Alexion Pharmaceuticals Inc. patent describes new complement C1s subcomponent (C1S) inhibitors potentially useful for the treatment of immune thrombocytopenia purpura, lupus nephritis, amyotrophic ...
In my November 2024 column, I began discussing the building block approach for crashworthiness testing of composite structures. This approach features a multistep process for designing composite ...
In my two previous columns, I discussed the lower and intermediate levels of the building block approach for crashworthiness testing and analysis of composite structures. I focused on the commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback